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Summary Two and four treatments of 5mmolkg-1 of buthionine sulfoximine (BSO) at an interval of 12h
depleted the glutathione (GSH) content in NFSa tumours of C3H/He mice, respectively, to 24.0 and 1.78
percent of the untreated controls. BSO pre-treatments every 12h enhanced the cytotoxicity of
cyclophosphamide (CYC) towards artificial lung micrometastases of NFSa tumours giving enhancement ratios
(ERs) ranging from 1.75 to 1.83 and from 2.41 to 2.73, for two and four BSO pretreatments respectively.
Large ERs were obtained at low CYC doses (high cell survival). Four BSO pre-treatments at an interval of
12h did not increase the cytotoxicity of CYC to bone marrow stem cells. Our results suggest a clinical
applicability of the combination of BSO and CYC.
Cellular sulfhydryls, especially glutathione (GSH),
have been found to protect cells via detoxification
of alkylating agents such as nitrogen mustard
(Arrick & Nathan, 1984). In fact, the relationship
between the sensitivity of tumour cells to nitrogen
mustard and their sulfhydryl contents has been
demonstrated by several investigators (Hirono,
1961; Calcutt & Connors, 1963; Ball et al., 1966;
Goldberg, 1969; Morita, 1973; Begleiter et al.,
1983). Additionally, the increased sensitivity of cells
to melphalan following either the incubation of
cells in cysteine-deficient medium or exposure to a
non-protein sulfhydryl (NPSH) depleting agent,
such as diethyl maleate (DEM) or buthionie sulf-
oximine (BSO), has been reported by several groups
(Suzukake et al., 1982; Taylor et al., 1982; Green et
al., 1984).
Cyclophosphamide (CYC) is a widely used
alkylating agent. According to the generally
accepted mechanism for the generation of active
metabolites, CYC becomes phosphoramide mustard,
one of the nitrogen mustards, via oxidation to
4-hydroxycyclophosphamide in liver. Additionally,
in other pathways for 4-hydroxycyclophosphamide,
a formation of sulfhydryl reactive intermediates
has been suggested (Ludlum, 1977; Cates & Li,
1982). Therefore, the pretreatment of tumours with
an NPSH depleting agent may potentiate the
response of tumours to CYC. In fact, it has been
reported that an increase in the response of murine
tumours to CYC was obtained by a single treat-
ment of BSO (Tomoshefsky et al., 1985). The com-
bination of BSO and CYC may have therapeutic
benefit because the changes of GSH contents in
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tissues following BSO treatments differ greatly
from tissue to tissue (Griffith & Meister, 1979;
Minchinton et al., 1984; Yu & Brown, 1984) and
an optimal administration schedule of BSO may
decrease the GSH content in tumours, but not in
target organs of CYC.
One of the important roles of chemotherapy in
cancer treatments is to eradicate micrometastases of
tumours. In this study, we have examined the
combined effect of multiple BSO pre-treatments
and CYC on artificial lung micrometastases of
murine tumours and bone marrow toxicity in mice.
Materials and methods
Mice and tumours
Eight week old C3H/He male mice obtained from
the animal centre of Kyoto University were used.
They were caged in groups of 10 or less at a
constant temperature with food and drinking water
available ad libitum.
A fibrosarcoma, NFSa which arose spon-
taneously in a C3H mouse (Ando et al., 1979),
were provided by Dr. K. Ando (National Institute
of Radiological Science, Chiba, Japan). The 17th
generation of tumour was cryopreserved. When
required, the contents of an ampoule were thawed
and transplanted into a number of recipient mice.
The outgrowing tumours were excised and minced.
Tumour cell suspensions were then prepared
enzymatically (0.2% trypsin, 0.02% pancreatin).
After cell counting, _104 viable cells in 10p1 were
inoculated s.c. into both thighs of the new recipient
mice. Tumour from this 19th transplant generation
reached a volume of 500mm3 14 days after inocu-
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lation. At this tumour volume, changes in NPSH
content of tumours after BSO treatment were
studied. For the study on the effect of cytotoxic
treatments, artificial lung micrometastases were
produced by injecting the viable tumour cells via
the tail vein of the recipient mice. Ten days later,
these micrometastases became macroscopic tumour
nodules on the surface of the lung. In order to
increase the formation rate of the tumour nodules
in the lung, mice were treated with 150mgkg-1
CYC 24h previously and HIR (heavily irradiated,
100Gy) tumour cells were mixed with the viable
cells (Ando et al., 1984). A total of 2 x 106 tumour
cells in 0.5ml were injected. The number of tumour
nodules was directly proportional to the number of
the viable tumour cells injected, and tumour
nodules were enumerated up to 100 per lung. The
formation rate of the tumour nodules in the lung of
the control was -5%. Therefore, to construct the
dose survival curve of the lung micrometastases, the
mixture of HIR and the appropriate number of
viable tumour cells which were expected to produce
about 50 nodules after CYC treatment with or
without BSO were injected via the tail vein. In 2 to
5 separate experiments, 10 to 25 mice in total were
used for each point.
Drug treatment
BSO was prepared as described by Griffith and
Meister (1979), and dissolved in sterile physiological
saline (400mM). For measurement of NPSH
contents in the tumours after BSO treatment,
5mmolkg-' BSO was injected s.c. into the
posterior neck of mice 2 or 4 times every 12h.
Twelve hours after final injection of BSO, the
tumours were excised and their NPSH contents
were measured. For study of the combined effect of
multiple BSO pretreatments and CYC toward lung
micrometastases, 5mmolkg-1 BSO was injected
every 12h in the manner described above. The BSO
treatment was 48h after i.v. injection of the tumour
cells when BSO was administered twice every
12h. When given four times, BSO was started 24h
after tumour cell injection. CYC was dissolved in
physiological saline and was administered i.p. 12h
after the final BSO treatment, 72h after tumour cell
injection, in either BSO treatment schedule. To
study bone marrow toxicity of the drugs, CYC was
administered i.p. to non-tumour-bearing mice in
combination with or without 4 injections of
5mmolkg 1 BSO on the schedule described above.
Non-protein suithydryl (glutathione, cysteine)
measurement
This assay has been described in detail elsewhere
(Komuro et al., 1985). Briefly, 10% homogenates
of tumours were prepared in 0.02M ethylene
diamine tetra acetic acid-disodium (EDTA) on ice.
Aliquots (2.5ml) of the homogenates were diluted
with 2ml H20 and 0.5ml 50% trichloroacetic acid.
The mixture was shaken vigorously and kept at 0°C
for 15min. The suspensions were centrifuged at
2000g and 4°C for 10min. Two ml of the super-
natant were added to 4ml of 0.4M Tris buffer (pH
8.9), and 0.1ml of 0.01MDTNB was added and
shaken. After filtering through a 0.22gm millipore
filter (Millipore, Bedford, MA, USA) absorbance at
412nm of the sample solution was recorded on a
spectrophotometer (UVIDEC 610 Spectrophoto-
meter, Jasco, Tokyo, Japan) for the measurement
of total non-protein sulfhydryl (NPSH). The sample
was subjected to high-performance liquid
chromatography (Hitachi Model 655 Solvent
Delivery System, Tokyo, Japan) for measurement
of GSH and cysteine content.
Measurement oflung micrometastases andbone
marrow response
Lungs were removed 10 days after treatment and
fixed in Bouin's solution, and tumour nodules on
the surface of the lungs were counted by eye.
Surviving fractions of the lung micrometastases
were obtained by dividing the formation rates of
the tumour nodules at the CYC doses administered
by that of the control.
Drug effects on normal bone marrow were
determined by the spleen colony assay (Till &
McCulloch, 1961). Femurs from both legs of mice
without tumours were removed 24h after CYC
treatment, and the marrow was washed out with
1 ml of cold physiological saline. Bone marrow
suspensions from 3 mice were combined, nucleated
cells counted and an adequate number of cells were
then injected i.v. into 7 mice which had received
wholebody gamma-irradiation (9Gy) 24h pre-
viously. Spleens were removed 8 days later, fixed in
Bouin's solution and the numbers of colonies
counted.
Results
Non-protein sulfJhydryl (glutathione, cysteine)
depletion by BSO
Figure 1 shows the changes of NPSH, GSH, and
cysteine contents in NFSa tumours after repeated
administration of 5mmolkg-' of BSO. NPSH
content in untreated tumours was 2.590mmolkg-1
which involves 2.067 mmolkg-' of GSH and 0.301
mmolkg-' of cysteine. Two BSO treatments given
at 12h intervals reduced the NPSH, GSH and
cysteine contents of tumours to 36.9, 24.0 andCHEMOSENSITIZATION BY BSO 751
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Figure 1 The changes of NPSH (0), GSH (EI), and
cysteine (A) contents in NFSa tumours of C3H/He
mice following repeated administration of BSO
(5mmolkg-1). Vertical lines represent s.d. of 6
tumours. BSO was administered repeatedly at the time
indicated by vertical arrows.
84.7% of the untreated levels, respectively, 12h
after the second BSO treatment. Following four
BSO treatments, the contents of NPSH, GSH and
cysteine in tumours decreased to 14.1, 1.78, and
42.9% of the untreated levels, respectively, 12h
after the fourth BSO treatment.
Effects on lung micrometastases ofNFSa tumour
The response of lung micrometastases which were
treated with CYC 12h after tumour cell injection
was described by an exponential survival curve with
a small shoulder (Figure 2). When CYC treatment
was 72h after tumour cell injection, the dose
survival curve was an exponential curve with an
almost equal slope, but a large shoulder compared
with the former (Figure 2). The cytotoxic effect of
CYC on lung micrometastases was markedly
enhanced when CYC was given to mice after two
or four BSO treatments (Figure 3). Enhancement
ratios (ERs) ranging from 2.41 (SF=5%) to 2.73
(SF=80%) were obtained when four BSO treat-
ments were given before CYC administration. In
the case of two BSO treatments, they ranged from
1.75 (SF=5%) to 1.83 (SF=40%). The average
colony formation rate was 5.0% throughout
these experiments and was not affected by BSO
treatments.
CFU-S sensitivity studies
The results of dose response studies of CFU-S to
CYC in combination with orwithout BSO treatments
are presented in Figure 4. Four BSO treatments
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Figure 2 The surviving fractions of artificial lung
micrometastases treated with CYC 12 (A) and 72
(@)h after tumour cell injection via the tail vein of
mice. Vertical lines represent s.d. of 2 to 5 separate
experiments.
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Figure 3 The surviving fractions of 72h old artificial
lung micrometastases treated with CYC alone (0) or
in combination with 2 ([1) and 4 (0) BSO pre-
treatments (5mmolkg-1). Vertical lines represent s.d.
of 2 to 5 separate experiements.
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so administered at 12h intervals, because the
maximum GSH depletion in NFSa tumours (45%
of the untreated) was achieved 12h after a single
treatment with BSO (Ono et al., 1986). The
- repeated BSO treatment depleted the tumour GSH
to very low levels, according to the number of BSO
administrations (Figure 1), and did not exhibit any
untoward effects such as weight loss or death of
a \ mice. Therefore, repeated administration of BSO
- r' \alone on an optimal schedule appears to be a
sufficient and safe method to deplete tumour GSH
to very low levels.
The survival curves of 12 and 72 h old lung
micrometastases have almost the same slopes
(Figure 2). This finding may indicate that tumour
cells in the micrometastases of both age groups
have similar sensitivities to CYC and similar proli-
feration status, since CYC has been known to
-- ' ' ' ' ' ' exhibit smaller cytotoxicity towards noncycling
100 200 300 tumour cells compared with cycling cells (Begg et
Dose of CYC (mg kg-1) al., 1985). The survival curve of 72h old micro-
I The surviving fractions of CFU-S of bone metastases has a wider shoulder compared with
cells treated with CYC alone (0) or in that of 12h old micrometastases (Figure 2). This
ition with four pre-treatments of BSO may be due to the proliferation of cells in the lung
kg-1 (Q). Vertical lines represent s.d. of two prior to treatment leading to a greater cell number
experiments. (multiplicity) in the 72h-old vs. 12h-old lung
micrometastases.
In our experiments, the yield of tumour nodules
affect the cytotoxicity of CYC on bone in the lung was not affected by BSO treatment.
CFU-S. Rojas et al. (1984) reported that BSO treatment did
not inhibit the growth of tumours. However,
Midander and Revesz (1984) reported that BSO at
in high doeses and long exposure time showed cyto-
toxicity and growth inhibitory effects toward V79
nges in GSH contents in tumours of mice cells. Pronounced cytotoxic effects of prolonged
O treatment have been examined by several exposure to high doses of BSO were observed in
tors. Minchinton et al. (1984) reported other cell lines (Shrieve & Harris, 1986). In in vitro
n GSH depletion down to 38% in the systems, BSO at low doses and short exposure time
tumour and 57% in SAFA tumour, has not exhibited cytotoxicity (Shrieve et al., 1985).
ely, 8 or 12h after treatment with It has been reported that BSO administered to mice
g-I of D, L,-BSO. Rojas et al. (1984) is completely excreted or metabolized within 24h
he same lines of tumours repeatedly with a (Griffith, 1982). Therefore, the discrepancy between
se of 0.5 or 1.0mmolkg-1, but maximum the results may be caused by the different BSO
pletion was to 37.8% of the control values. exposure times.
Brown (1984) have reported that GSH BSO increased the sensitivity of the lung micro-
in EMT6 and KHT tumours treated with metastases of NFSa tumour cells to CYC (Figure 3).
doses, higher than 0.33mmolkg-1, Further, this increase appears to correlate inversely
d to minimum levels 6 to 8h after the with the GSH level at the time of CYC treatment,
it, and complete recovery in GSH contents because four BSO treatments decreased GSH
ieved by 24h. They also reported that the content of NFSa tumours to a lower level
ntents in five different tumour lines treated compared with two BSO treatments. Tomashefsky
ily doses of 1 or 3 mmolkg-I of BSO et al. (1985) have reported a similar phenomenon,
d, respectively, to 20-50%, and 19-40% of showing that the growth delay time of MBT-2
rol values. In order to get further GSH tumour, a transplantable murine bladder tumour,
i they combined DEM (300mgkg-1) with after CYC treatment correlated inversely with GSH
iulting in a decrease to 8% of the control contents. Somfai-Relle et al. (1984) have also
our studies, 5 mmol kg-I of D, L,-BSO was reported that the sensitivity of L1210 leukaemiaCHEMOSENSITIZATION BY BSO 753
cells to L-PAM becomes higher with longer BSO
treatments (i.e., at lower GSH levels).
In our studies, the ERs of BSO treatments were
large at high survival levels (i.e., at small CYC
doses). This finding may be applicable to cancer
therapy, because small doses of CYC are adminis-
tered repeatedly in clinical cancer chemotherapy.
The sensitivity of bone marrow cells to CYC did
not increase after BSO treatment (Figure 4). More-
over, BSO did not affect the yield of nucleated cells
per femur (data not presented). It is not possible by
available methods to measure the GSH content of
bone marrow stem cells. However, GSH content in
whole bone marrow cells decreased to minimum
levels and completely recovered, 4 and 12h respec-
tively after the treatment with 5mmolkg-1 of
D, L,-BSO (Komuro et al., unpublished). Therefore,
it seems probable that the treatment with BSO at
an interval of 12h did not decrease the GSH
content in bone marrow stem cells to levels low
enough to increase the sensitivity to CYC.
In conclusion, our results suggest that multiple
BSO treatment on an appropriate administration
schedule can increase the sensitivity of tumours to
CYC without changing that of bone marrow stem
cells. However, more toxicity studies on other
critical normal tissues (e.g. gut) are needed before
clinical application can be considered.
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